Literature DB >> 9524412

Treatment of persistent Pfiesteria-human illness syndrome.

R Shoemaker.   

Abstract

Patients with exposure to Pfiesteria toxin have developed an illness, Pfiesteria-human illness syndrome, characterized by skin lesions, headache, myalgias, conjunctival irritation, bronchospasm, abdominal pain, secretory diarrhea, recent memory loss, and difficulties with number sequencing. Not all patients demonstrated all features of the syndrome. The natural history of Pfiesteria-human illness syndrome shows that most patients' symptoms improve without treatment. This article reports the improvement of symptoms that had persisted for over one month in five patients, which the author attributes to treatment with cholestyramine. These patients were self-referred to the Pocomoke River Rash and Associated Illness Center, a clinic that opened on August 6, 1997, in response to the need for a central facility for diagnosis of human illness acquired from Pfiesteria. Until the Pfiesteria toxin(s) is isolated and characterized, and laboratory diagnostic tests are available, physicians must be able to recognize Pfiesteria-human illness syndrome and intervene when symptoms, particularly memory loss and diarrhea, cause significant impairment in daily activities. There are no precedents for the treatment of Pfiesteria or any dinoflagellate toxin-related human illness reported in the literature. The successful use of cholestyramine reported here may provide a model for understanding dinoflagellate toxin physiology in the human body. This paper reports an uncontrolled observational study. When identification of the toxin is completed, a basis for properly controlled studies will be available.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9524412

Source DB:  PubMed          Journal:  Md Med J        ISSN: 0886-0572


  7 in total

1.  Are Pfiesteria species toxicogenic? Evidence against production of ichthyotoxins by Pfiesteria shumwayae.

Authors:  J P Berry; K S Reece; K S Rein; D G Baden; L W Haas; W L Ribeiro; J D Shields; R V Snyder; W K Vogelbein; R E Gawley
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-05       Impact factor: 11.205

Review 2.  Pfiesteria: review of the science and identification of research gaps. Report for the National Center for Environmental Health, Centers for Disease Control and Prevention.

Authors:  J Samet; G S Bignami; R Feldman; W Hawkins; J Neff; T Smayda
Journal:  Environ Health Perspect       Date:  2001-10       Impact factor: 9.031

3.  Residential and recreational acquisition of possible estuary-associated syndrome: a new approach to successful diagnosis and treatment.

Authors:  R C Shoemaker
Journal:  Environ Health Perspect       Date:  2001-10       Impact factor: 9.031

4.  Possible estuary-associated syndrome: symptoms, vision, and treatment.

Authors:  R C Shoemaker; H K Hudnell
Journal:  Environ Health Perspect       Date:  2001-05       Impact factor: 9.031

5.  Pfiesteria in estuarine waters: the question of health risks.

Authors:  Ritchie C Shoemaker; Wayne Lawson
Journal:  Environ Health Perspect       Date:  2007-03       Impact factor: 9.031

6.  Lack of evidence for contact sensitization by Pfiesteria extract.

Authors:  Rachel M Patterson; Edward Noga; Dori Germolec
Journal:  Environ Health Perspect       Date:  2007-07       Impact factor: 9.031

7.  Rapid Health Impact Assessment of a Proposed Poultry Processing Plant in Millsboro, Delaware.

Authors:  Leah Baskin-Graves; Haley Mullen; Aaron Aber; Jair Sinisterra; Kamran Ayub; Roxana Amaya-Fuentes; Sacoby Wilson
Journal:  Int J Environ Res Public Health       Date:  2019-09-16       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.